Added to YB: 2024-12-23
Pitch date: 2024-10-10
RXST [bullish]
RxSight, Inc.
-74.79%
current return
Author Info
No bio for this author
Company Info
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.
Market Cap
$400.1M
Pitch Price
$49.73
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.60
P/E
-11.07
EV/Sales
1.30
Sector
Health Care Equipment and Supplies
Category
growth
Brown Capital Management Small Company Fund Portfolio Holding: RxSight, Inc.
RXST: Only FDA-approved light adjustable lens for cataract surgery. 50%+ annual revenue growth to $89M in 2023. Premium IOL market at 20% US/11% global penetration. 25%+ future growth expected, profitability by 2026. Experienced management team. Superior product for patients/physicians.
Read full article (1 min)